Literature DB >> 9444882

Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization.

R H Snider1, E S Nylen, K L Becker.   

Abstract

BACKGROUND: The systemic inflammatory response syndrome (SIRS) is a marked, generalized response to a variety of injuries, if infection is implicated, the term "sepsis" is used. Systemic inflammatory response syndrome/sepsis, which is initiated by proinflammatory cytokines, has been found to be associated with increased serum levels of the prohormone of calcitonin, procalcitonin (ProCT) and its aminoterminus peptide (nProCT). The serum levels of ProCT and nProCT are very useful markers for SIRS/sepsis, and may be used to follow the course, the response to therapy, and/or the prognosis. We studied the serum levels and distribution of ProCT and its component peptides in normal persons for comparison with similar immunochemical and separatory studies in patients with neuroendocrine cancer and with SIRS/sepsis of various etiologies.
METHODS: We studied pooled and extracted serum of 13 normal subjects, and sera of patients with neuroendocrine cancer and SIRS/sepsis, using region-specific immunoassays, gel filtration, and high performance liquid chromatography.
RESULTS: Normal sera contained small but measurable levels of the intact ProCT molecule, nProCT, a conjoined calcitonin-calcitonin carboxyterminal peptide (CT:CCP-I), CCP-I, free mature CT, and calcitonin gene-related peptide (CGRP). Sera from neuroendocrine cancer usually contained high levels of these peptides. In such cases, free mature CT was always increased, the mean ratio of the intact ProCT to free CT being 168 +/- 68. Gel filtration and HPLC studies of patients with SIRS/sepsis revealed markedly increased levels of ProCT, nProCT, and CT:CCP-I in varying proportions. Mature CT was normal to minimally elevated. The ratio of ProCT to free CT was 2,900 +/- 800. Although serum CGRP is commonly increased in neuroendocrine cancer, it was very low or undetectable in SIRS/sepsis.
CONCLUSIONS: These studies indicate that ProCT and its component peptides circulate in normal persons. The serum of patients with SIRS/sepsis contains greatly increased levels of ProCT, nProCT and often, CT:CCP-I. However, in this condition, post-translational processing is incomplete, resulting in mature CT levels that are normal or minimally elevated. In contrast, patients with neuroendocrine cancer have considerably high mature CT levels. Interestingly, although serum CGRP levels often are high in neuroendocrine cancer, they are low in SIRS/sepsis. The marked hyperprocalcitonemia of SIRS/sepsis is probably a consequence of the pro-inflammatory cytokine cascade, and appears to be secreted in a constitutive fashion; the cell(s) of origin of this remarkable hypersecretion is unknown. There is a very marked positive correlation between serum levels of ProCT and nProCT, and the lower level of sensitivity for nProCT may make its measurement a more useful marker for early or mild SIRS/sepsis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9444882

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  41 in total

Review 1.  Immune regulation of procalcitonin: a biomarker and mediator of infection.

Authors:  G N Matwiyoff; J D Prahl; R J Miller; J J Carmichael; D E Amundson; G Seda; M Daheshia
Journal:  Inflamm Res       Date:  2012-02-22       Impact factor: 4.575

2.  [Diagnostic laboratory guideline for assessment of functional disorders and diseases of the thyroid gland].

Authors:  Christian Bieglmayer; Wolfgang Buchinger; Manuela Födinger; Mathias M Müller; Pranav Sinha; Marietta Vogl; Michael Weissel; Wolfgang Zechmann
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 3.  Biomarker discovery and development in pediatric critical care medicine.

Authors:  Jennifer M Kaplan; Hector R Wong
Journal:  Pediatr Crit Care Med       Date:  2011-03       Impact factor: 3.624

Review 4.  Procalcitonin: present and future.

Authors:  H H Liu; J B Guo; Y Geng; L Su
Journal:  Ir J Med Sci       Date:  2015-07-10       Impact factor: 1.568

5.  Pre-emptive antibiotic treatment vs 'standard' treatment in patients with elevated serum procalcitonin levels after elective colorectal surgery: a prospective randomised pilot study.

Authors:  Ansgar Michael Chromik; Frank Endter; Waldemar Uhl; Arnulf Thiede; Hans Bernd Reith; Ulrich Mittelkötter
Journal:  Langenbecks Arch Surg       Date:  2005-12-21       Impact factor: 3.445

Review 6.  Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.

Authors:  Kenneth L Becker; Richard Snider; Eric S Nylen
Journal:  Br J Pharmacol       Date:  2009-11-27       Impact factor: 8.739

Review 7.  Overview of procalcitonin in pregnancy and in pre-eclampsia.

Authors:  A Mangogna; C Agostinis; G Ricci; F Romano; R Bulla
Journal:  Clin Exp Immunol       Date:  2019-06-13       Impact factor: 4.330

8.  Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis.

Authors:  Hui-Min Wu; Juan Wei; Jin Li; Kai Wang; Lei Ye; Ying Qi; Bo-Si Yuan; Yu-Lin Yang; Li Zhao; Zhao Yang; Miao-Fang Yang; Jian-Feng Gong; Fang-Yu Wang
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

Review 9.  Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia.

Authors:  Mirjam Christ-Crain; Steven M Opal
Journal:  Crit Care       Date:  2010-02-08       Impact factor: 9.097

10.  Serum and pleural fluid procalcitonin in predicting bacterial infection in patients with parapneumonic effusion.

Authors:  Yang-Ching Ko; Wen-Pin Wu; Chi-Sen Hsu; Mong-Ping Dai; Chien-Chih Ou; Chih-Hsiung Kao
Journal:  J Korean Med Sci       Date:  2009-06-12       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.